Italy’s Zambon Co. SPA has paid an initial €140m to acquire the VC-backed German/US biotech, Breath Therapeutics Holding BV in a move that strengthens the specialty products pipeline of the mid-sized European pharmaceutical company, brings US-based clinical and regulatory expertise, and provides a significant return for investors in Breath Therapeutics, which raised €43.5m in a series A round in 2017.
The deal is the largest in Milan-headquartered Zambon’s history and adds a second potential therapeutic candidate to the company’s late-stage...








